Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TER-EYE: MSC Injection Therapy for Refractory GVHD
NCT06905834Phase 2Not yet recruiting
- Sponsor
- Hospital Universitario de Salamanca
- Start
- Dec 2026
- Primary completion
- Jan 2029
- Modality
- Stem Cell Therapies
01
Overview
A Phase 2 trial of allogeneic adult adipose-derived mesenchymal stem cells in graft-versus-host disease (GVHD), dry eye disease (DED), sponsored by Hospital Universitario de Salamanca. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
allogeneic adult adipose-derived mesenchymal stem cells
03
Conditions
graft-versus-host disease (GVHD)dry eye disease (DED)
Beyond the preview
Go deeper on NCT06905834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06905834.